TransCelerate BioPharma was formed in 2012 as a non-profit organization with a mission to collaborate across the biopharmaceutical research and development community to identify, prioritize, design and facilitate the implementation of solutions to drive efficient, effective and high-quality delivery of new medicines.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Acknowledgements
The founder members of Transcelerate BioPharma are AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, the Roche Group, and Sanofi. Additional members that have joined include Allergan, Astellas Pharma, Biogen Idec, Cubist Pharmaceuticals, EMD Serono (a subsidiary of Merck KGaA, Darmstadt, Germany), Forest Research Institute (a subsidiary of Forest Laboratories), Medgenics, Shionogi & Co. and UCB.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Related links
Related links
FURTHER INFORMATION
Rights and permissions
About this article
Cite this article
Gill, D. Re-inventing clinical trials through TransCelerate. Nat Rev Drug Discov 13, 787–788 (2014). https://doi.org/10.1038/nrd4437
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4437
